Oxford BioDynamics has secured its first commercial agreement with a major pharmaceutical company for its EpiSwitch® Orion platform, entering into a partnership with Johnson & Johnson for a biomarker discovery programme focused on inflammatory bowel disease (IBD).
The agreement represents the first time a pharmaceutical company has paid to use EpiSwitch® Orion, marking a further step in the commercialisation of the company’s cloud-based 3D genomics technology. It follows OBD’s first commercial Orion agreement, announced on 28 July 2026, with the University of Oxford-led OPTIMISE psoriatic arthritis programme.
Under the new agreement, OBD will process genotype data from a cohort of patients with IBD to identify baseline biomarkers that could help predict their response to biologic therapies. The programme is intended to establish whether specific genetic and regulatory features can distinguish patients who are more likely to respond to treatment before therapy begins.
The work will cover patients with both Crohn’s disease and ulcerative colitis, the two main forms of IBD. Several hundred genotyped patient samples will be analysed in stages, with an initial panel of markers identified and refined using a training cohort. The resulting predictive classifier will then be assessed against an independent, blinded validation cohort to evaluate its performance.
OBD’s responsibilities will include data processing, anchor mapping, statistical analysis, machine learning model development and validation. The company will also provide dedicated project management and technical support throughout the programme.
EpiSwitch® Orion is OBD’s cloud-based 3D genomics discovery platform, designed to convert standard genome sequencing and genotype data, including existing datasets, into 3D regulatory intelligence. The technology uses a curated 3D genomics knowledgebase to investigate disease-associated genetic variations in non-coding regions of the genome.
According to OBD, these regions account for approximately 90-95% of disease-associated variants that traditional sequencing and genome-wide association approaches cannot decipher. By examining the regulatory structures that influence how genes operate, the platform aims to help pharmaceutical and biotechnology companies identify potential drug targets and biomarkers.
The Johnson & Johnson agreement provides a commercial application for this technology within pharmaceutical research, particularly in the identification of patients who may benefit from specific treatments. The ability to use existing genotype datasets also provides a potential route for applying the platform to established patient cohorts without requiring entirely new sequencing programmes.
Richard Compton, Chief Executive Officer of Oxford BioDynamics, said:
“This agreement marks an important commercial milestone for EpiSwitch® Orion – the first time a pharmaceutical company has paid to use the platform. Helping identify likely responders earlier addresses a genuine need in inflammatory bowel disease, and we’re pleased to see this growing interest in Orion’s commercial use. It reflects the strength of the platform we’ve built and gives us real confidence in Orion’s commercial trajectory. We expect this to be the first of several such agreements, and we’ll update shareholders as the programme, and wider commercialisation of Orion, develops.”
Oxford Biodynamics plc (LON:OBD) is a global biotech company advancing personalized healthcare by developing & commercializing precision medicine tests for life-changing diseases.









































